Avastin 400mg injection

Avastin 400mg injection

Prescription requiredRx Required
Refrigerated 2–8°C · Online payment only

Salt Composition: Bevacizumab

Expiry Date: 01/2028

Special offer

Enquire

Inclusive of all taxes

▼

1 Vial

About The Product

Avastin 400mg injection belongs to the category of anticancer medicines. This medicine is primarily used to treat patients diagnosed with brain cancer, cervical cancer, kidney cancer, lung cancer, ovarian cancer, and colorectal cancer. The growth of cancer cells is uncontrollable and abnormal in the human body. It is difficult to diagnose cancer in the early stages.

When diagnosed in advanced stages, only the symptoms of the disease can be reduced. Avastin injection is typically administered in combination with another anticancer medication as part of a combination therapy to enhance the treatment's efficacy. It is given as an infusion, which means it is given into the veins through a small needle or port (device placed under your skin).

Overview

Avastin 400mg/16mL injection contains bevacizumab, a recombinant humanized anti-VEGF (vascular endothelial growth factor) monoclonal antibody manufactured by Roche/Genentech. Avastin 400mg/16mL injection was the first anti-angiogenic oncology therapy approved (2004 for colorectal cancer) and remains one of the most widely used cancer biologics globally.

It works by binding VEGF-A and blocking tumor angiogenesis—cutting off the blood supply that tumors need to grow and spread. Avastin 400mg/16mL injection is approved for 8+ tumor types.

Critical combination: Atezo+Bev (Tecentriq+Avastin) is the standard first-line therapy for advanced HCC. Avastin 400mg/16mL injection is administered with chemotherapy across multiple indications and is not active as a single agent.

Patients and caregivers in India can find information about Avastin 400mg/16mL injection availability, prescription verification, and treatment access support.

Quick Product Facts

Brand Name

Avastin

Generic Name

Bevacizumab

Drug Class

Anti-VEGF Monoclonal Antibody — Recombinant Humanised IgG1

Manufacturer

Roche / Genentech

Dose

5mg/kg or 10mg/kg or 15mg/kg Q2W or Q3W — indication-dependent

Route

IV infusion — 90 min (first); 60 min (second); 30 min (subsequent)

Key Combination

Atezo+Bev for HCC | + Chemo for CRC, NSCLC, Ovarian, Cervical

Storage

Refrigerate 2°C–8°C. Protect from light. Do NOT freeze.

Prescription

Yes — Oncologist mandatory

Uses and Indications

Colorectal Cancer (CRC) — First and Second-Line

Avastin 400mg/16mL + FOLFOX/FOLFIRI/XELOX for metastatic CRC. First-line: 5mg/kg Q2W or 7.5mg/kg Q3W. Second-line: 5mg/kg Q2W with FOLFIRI after first-line oxaliplatin-based failure. Established survival benefit in multiple CRC trials (AVF2107, E3200).

Non-Small Cell Lung Cancer (NSCLC) — Non-Squamous

Avastin 15mg/kg + Carboplatin + Paclitaxel Q3W for advanced non-squamous NSCLC. Also Atezolizumab + Bev + Carbo + Paclitaxel (ABCP regimen—IMpower150). NOT for squamous histology (haemorrhage risk).

Ovarian Cancer

First-line: Avastin 400mg/16mL + Carboplatin + Paclitaxel for Stage III/IV ovarian cancer; maintenance 15mg/kg Q3W for 12-22 cycles (ICON7/GOG-0218). Also platinum-resistant recurrence.

Hepatocellular Carcinoma (HCC)—Atezo+Bev

Atezolizumab 1200mg + Avastin 15mg/kg IV Q3W for unresectable HCC (IMbrave150). Now the global standard of care is first-line. Variceal screening is mandatory before starting.

Other Indications

Cervical cancer (+ platinum + paclitaxel ± topotecan), glioblastoma (after progression), Renal cell carcinoma.

How It Works

  • An anti-angiogenic medication, Avastin 400mg injection, works by blocking vascular endothelial growth factor (VEGF), which is a protein.

  • It basically functions by cutting the oxygen supply and nutrients to cancerous cells by stopping the formation of blood vessels that supply them.

Clinical Evidence

IMbrave150 (HCC — Atezo+Bev)

Atezo 1200mg + Bev 15mg/kg vs Sorafenib Q3W for first-line unresectable HCC. OS: 19.2 vs 13.4 months. PFS: 6.8 vs 4.3 months. ORR 27.3% vs 11.9%. Changed global HCC treatment standard.

GOG-0218 (Ovarian Cancer)

Avastin 400mg/16mL + Carboplatin + Paclitaxel → Avastin  400mg/16mL Injection maintenance for Stage III/IV ovarian cancer. PFS: 14.1 vs 10.3 months for maintenance arm. OS benefit in high-risk subgroups. Established Avastin 400mg/16mL Injection in front-line ovarian cancer.

AVF2107 (Metastatic CRC — First-Line)

Avastin 400mg/16mL + IFL chemotherapy vs IFL alone for first-line mCRC. OS: 20.3 vs 15.6 months. ORR 44.8% vs 34.8%. First clinical proof of anti-angiogenic benefit in CRC — landmark 2004 approval trial.

KEYNOTE-826 (Cervical Cancer — Pembrolizumab ± Bev)

Pembrolizumab + Chemo ± Avastin for metastatic cervical cancer. The Avastin 400mg/16mL Injection arm added further PFS and OS benefit on top of immunotherapy + chemotherapy.

Side Effects

The human body shows undesired symptoms after taking the Avastin 400mg injection. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable. Some of the side effects of Avastin injection are mentioned below:

Common side effects

  • Fever

  • Fatigue

  • Back pain

  • Headache

  • Mouth sore

  • Weight loss

  • Constipation

  • Nose bleeding

  • Breathlessness

  • Taste alteration of appetite

  • Abdominal pain, increased heart rate

  • High blood pressure

  • Nausea and vomiting

  • Numbness in hands and feet.

Severe side effects

  • Gut infection

  • Blood clotting

  • Hemorrhage

  • Protein in urine

  • Decrease in the level of white blood cells

Critical Safety Warning

⚠ GI PERFORATION, HAEMORRHAGE, AND WOUND HEALING — CRITICAL RISKS

Avastin 400mg/16mL Injection carries three serious surgical and vascular risks: (1) GI perforation—can be life-threatening; stop immediately if suspected. (2) Serious hemorrhage—including pulmonary hemorrhage in NSCLC (not indicated in squamous histology) and CNS hemorrhage in brain metastases. (3) Wound healing impairment—do not administer within 28 days before or after surgery; do not restart until wound fully healed. Additionally: hypertension must be controlled before starting and monitored throughout. Proteinuria requires dose interruption if ≥2g/24h and permanent discontinuation for nephrotic syndrome.

⚠ INDICATION IN SQUAMOUS NSCLC

Avastin 400mg/16mL Injection is not indicated for squamous cell non-small cell lung cancer (NSCLC) due to significantly increased risk of life-threatening or fatal pulmonary hemorrhage (up to 31% in initial trials). Always confirm NSCLC histology before prescribing Avastin 400mg/16mL Injection.

Dosage and How To Take It

Avastin 400mg/16mL injection is administered by IV infusion. Do not give as IV bolus or push.

First infusion: 90 minutes. If tolerated: second infusion in 60 minutes. Subsequent infusions: 30 minutes if well tolerated.

  1. Colorectal cancer (first-line): 5mg/kg IV Q2W or 7.5mg/kg IV Q3W.

  2. NSCLC: 15mg/kg IV Q3W with chemotherapy (non-squamous ONLY).

  3. Ovarian cancer: 15mg/kg IV Q3W with chemotherapy, then maintenance.

  4. HCC (Atezo+Bev): 15mg/kg IV Q3W with Atezolizumab 1200mg.

  5. Cervical cancer: 15mg/kg IV Q3W with chemotherapy.

No dose reductions—modify by interruption or discontinuation based on toxicity.

The availability of Avastin 400mg/16mL injection in India is dependent on the stock as well as the cold-chain supply logistics. Both patients and caregivers may inquire regarding the availability, pan-India delivery, prescription verification, as well as the treatment access support related to Avastin 400mg/16mL Injection.

Missed Doses

  • It is advised not to miss any scheduled dosage of Avastin 400mg injection.
  • In case you miss a dose, consult your doctor immediately.
  • Don't overdose to compensate for the missed one.
  • Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Safety Advice

Alcohol

The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Avastin 400mg injection. It is advised to consult your doctor for further information.

Pregnancy

Avastin 400mg injection may be considered unsafe during pregnancy. Please consult your doctor in such condition.

Breast Feeding
Avastin 400mg injection is probably not safe if you're breastfeeding. Kindly consult your doctor.
Driving

It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking Avastin 400mg injection.

Kidney

Share your medical history with your healthcare expert in case of kidney disease before taking Avastin 400mg injection.

Liver

Inform your doctor before starting Avastin 400mg injection if you have liver disease to avoid any serious side effects.

Monitoring During Treatment

The following parameters must be monitored throughout treatment:

Parameter

Frequency

Action if Abnormal

Blood pressure

Each cycle, plus home monitoring

Antihypertensives for sustained elevation; hold for hypertensive crisis

Urine protein (dipstick → 24h if positive)

Each cycle

Hold for ≥2g/24h proteinuria; discontinue for nephrotic syndrome

Wound inspection

Before each infusion

Do not give if wound not fully healed; document healing status post-surgery

Liver function (HCC patients)

Q3W

Monitor hepatic reserve — Child-Pugh score relevant to Bev tolerability

Variceal assessment (HCC)

Before starting Atezo+Bev

Upper GI endoscopy; treat varices before starting Avastin 400mg/16mL Injection — haemorrhage risk

CBC

Each cycle (with chemo regimens)

Standard myelosuppression monitoring with combination chemotherapy

Fact Box

Parameter

Details

Brand Name

Avastin

Generic Name

Bevacizumab

Manufacturer

Roche / Genentech

First Approval

2004 — first anti-angiogenic therapy approved in oncology

Drug Class

Anti-VEGF Monoclonal Antibody — Recombinant Humanised IgG1 (rhuMAb VEGF)

Target

VEGF-A (Vascular Endothelial Growth Factor A)

Mechanism

Binds VEGF-A → blocks tumour angiogenesis → impairs tumour blood supply

Active as Monotherapy

No — must be combined with chemotherapy or immunotherapy

Standard Doses

5-15mg/kg Q2W or Q3W — indication-dependent

Critical Contraindication

Squamous NSCLC — pulmonary haemorrhage risk

Storage

Refrigerate 2°C–8°C. Protect from light. Do NOT freeze.

Prescription

Yes — Oncologist mandatory

Habit Forming

No

Drug Interactions

Drug / Class

Potential Interaction or Risk

What To Do

Platinum-based chemotherapy (Carboplatin, Cisplatin)

Increased renal toxicity risk.

Ensure adequate hydration and monitor renal function.

Taxanes (Paclitaxel, Docetaxel, Nab-paclitaxel)

Increased peripheral neuropathy risk.

Monitor for neuropathy throughout treatment.

Atezolizumab (Atezo + Bev)

Increased risk of hepatotoxicity and immune-related adverse events.

Monitor LFTs and immune-related toxicities regularly.

Anticoagulants (Warfarin, DOACs, LMWH)

Increased bleeding risk.

Monitor for bleeding and INR with warfarin.

Sunitinib

Risk of microangiopathic haemolytic anaemia (MAHA) and thrombotic microangiopathy.

Avoid concurrent use.

Surgery / wound management

Impaired wound healing due to VEGF inhibition.

Withhold for at least 28 days before and after major surgery, until adequate wound healing.

 

Always inform your treating oncologist about ALL medications, herbal supplements, and immunosuppressants before starting treatment.

FAQs

Avastin injection can pass through the mother's blood and harm the unborn baby.

So, it is advised not to give this drug to pregnant and breastfeeding women.

Reference

  1. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. (2023). Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 114(5):855-9

  2. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. (2024). Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 114(12):2179-82

  3. Oguchi Y, Sekiryu T, Omori T, Kato Y, Ogasawara M, Sugano Y, Itagaki K, Ojima A, Machida T, Sekine H. (2025). Anaphylatoxin concentration in aqueous and vitreous humor in the eyes with vitreoretinal interface abnormalities. Exp Eye Res;195:108025

  4. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML. (2023). Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27(4):439-44

  5. Kumar A, Sinha S. (2025). Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol. 55(6):451-5

  6. Kandasamy R, Constantinou M, Rogers SL, Sandhu SS, Wickremasinghe S, Al-Qureshi S, Lim LL. (2024). Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-month results. Br J Ophthalmol. 103(12):1753-1758.

  7. Taira K, Okazaki S, Akiyoshi K, Machida H, Ikeya T, Kimura A, Nakata A, Nadatani Y, Ohminami M, Fukunaga S, Otani K, Hosomi S, Tanaka F, Kamata N, Nagami Y, Fujiwara Y. (2023). Short bevacizumab infusion is an effective and safe treatment for colorectal cancer. Mol Clin Oncol. 17(3):139.

  8. Perdrizet K, Leighl NB. (2024). The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 18;20(3):21

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Magicine PharmacopyCopyright 2026